Drugs / Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06497465 Comparator | Sep 2025 → Jan 2028 expected | HIV infectious disease, tuberculosis | Johns Hopkins University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tenofovir disoproxil fumarate (TDF)/ lamivudine (3TC) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06497465 ↗ |